<scp>COVID</scp>
            ‐19 vaccine‐induced urticarial vasculitis

Currently the most powerful tool in combating the COVID‐19 pandemic is vaccination against SARS‐CoV‐2. A growing percentage of the world's population is being vaccinated. Various vaccines are worldwide on the market. Several adverse reactions have been reported as a part of post‐marketing surveillance of COVID‐19 vaccines. Among the possible adverse events, cutaneous vasculitis has occasionally been reported. We present a narrative review on cutaneous vasculitis related to COVID‐19‐vaccination to summarize clinical findings, histopathology, treatment and outcome. We searched for “COVID vaccine”, “COVID vaccination” AND “cutaneous vasculitis” in PUBMED. Articles in English have been selected, from inception to December 2021, and analyzed for patient's characteristics, type of vaccine, time of appearance of cutaneous vasculitis and clinico‐histopathologic type. Treatment and outcome have also been considered in this narrative review. Two new unpublished cases of ours were added. Cutaneous vasculitis is a rare adverse event to COVID‐19 vaccination. It has been observed with mRNA and adenovirus‐vector vaccines. IgA vasculitis, lymphocytic and ANCA‐associated vasculitis, leukocytoclastic and urticarial vasculitis have been reported. This adverse event can occur after first or second shot. Most cases run a mild to moderate course. Cornerstone of medical treatment are systemic corticosteroids. Complete remission could be achieved in most patients. Vasculitis may not be considered as a contraindication of vaccination, being uncommonly reported and shows a favorable prognosis. The benefit of the vaccination remains high especially for immunocompromised patients. COVID‐vaccine induced vasculitis is important in the differential diagnosis of purpuric and vasculitis disorders.

show abstract

“…Three cases were published in association with COVID‐19 vaccination. Two after the first dose of Moderna vaccine 34,38,48 …”

Section: Resultsmentioning

confidence: 99%

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

Abdelmaksoud

Wollina

Temiz

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…The first case of vaccine‐induced urticarial vasculitis, which was reported by Siddhartha Dash after the second dose of COVID‐19 vaccination for a patient who was not infected previously with COVID‐19 virus, suggested that the marked inflammatory response was the leading cause for vascular inflammation after the second dose. 7 In our case, it can be suggested that antigen had presented after COVID‐19 infection and the hypersensitivity inflammatory aroused after the first dose of vaccine, which mean that this patient has developed a considerable inflammatory response leading to this presentation. More studies are needed to know the exact type of the antibodies leading for this reaction.…”

Section: Figurementioning

confidence: 65%

Figurate purpuric eruption post‐COVID‐19 vaccination

Namazi

Diab

mardani

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Dear Editor, COVID-19 pandemic had spread rapidly all around the world leading to variety of manifestations that ranged from being asymptomatic to death. 1 While COVID-19 vaccination has played a very important role in ending this pandemic, adverse reactions are increasingly reported including cutaneous ones. Injection-site local reactions are among the most common reported cutaneous manifestations, followed by urticaria, pityriasis rosea-like lesions, and pernio/chilblains. 2 Herein we report a post-vaccine urticarial eruption that had unique presentation and could be considered a new urticarial variation following COVID-19 vaccination.Herein, we report a 58-year-old woman with no significant past medical history presented to our clinic with 1 week history of pruritic lesions on trunk and both lower extremities. The eruption had

show abstract

“…Reportedly, vasculitis accounted for 2.9 and 0.7% of the cutaneous side effects in patients receiving the first doses of Pfizer-BioNTech and Moderna (mRNA-1273) vaccines, respectively [ 11 ]. The disease was limited to cutaneous vasculitis in most patients [ 5 , 6 , 8 ]; however, organ involvement was reported in some cases. Shakoor et al.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 vaccination-related small vessel vasculitis with multiorgan involvement

et al. 2022

View full text Add to dashboard Cite

Since its first outbreak in 2019, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2, has been ongoing, and the pandemic is not over yet. Vaccines developed against COVID-19 have been approved and widely used since 2020; however, vaccine safety concerns need to be addressed. Autoimmune symptoms have been reported as a side effect of many COVID-19 vaccines. In particular, several cases of COVID-19 vaccine-induced vasculitis have recently been reported. Herein, we report the case of a 77-year-old woman who developed small-vessel vasculitis with multiorgan involvement after receiving the BNT162b2 COVID-19 vaccine (Pfizer and BioNTech, New York City, NY, USA).

show abstract

COVID ‐19 vaccine‐induced urticarial vasculitis

Cited by 37 publications

References 7 publications

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

Figurate purpuric eruption post‐COVID‐19 vaccination

COVID-19 vaccination-related small vessel vasculitis with multiorgan involvement

Contact Info

Product

Resources

About